More information: Aitor Morales-Gregorio et al, Neural manifolds in V1 change with top-down signals from V4 targeting the foveal region, Cell Reports (2024). DOI: 10.1016/j.celrep.2024.114371 ...
Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the U.S. Food and Drug ...
Pharmaceutical Technology on MSN4d
Atsena’s ATSN-201 gains FDA fast track status for XLRS treatmentThe Phase I/II LIGHTHOUSE trial is assessing the safety and tolerability of the gene therapy in male subjects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback